Immunovant (NASDAQ:IMVT) Issues Quarterly Earnings Results, Beats Estimates By $0.27 EPS

Immunovant (NASDAQ:IMVT) announced its quarterly earnings data on Monday. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.27, Zacks reports. During the same quarter in the prior year, the business earned ($0.73) earnings per share.

Here are the key takeaways from Immunovant’s conference call:

• LISRAYA generated $31 million in net revenue during its first five weeks on the market, with hundreds of patients on paid treatment and broad prescriber interest. Roivant said pharmacy inventory contributed a quarter-end tailwind that may modestly reverse in the December quarter, and cautioned that it is too early to extrapolate launch trends.
• In difficult-to-treat rheumatoid arthritis, IMVT-1402 at 600 mg maintained ACR20 responses in 92.5% of patients at the end of the randomized-withdrawal period, versus about 75% on placebo; 300 mg performed similarly to placebo. The company reported no new safety signals, but FDA discussions on the next trial’s design and approval path are ongoing.
• Roivant highlighted positive non-infectious uveitis results: treatment failure occurred at about 12 weeks for placebo patients, while median treatment failure was not reached beyond 48 weeks for brepocitinib-treated patients. The company plans to file a supplemental application for the indication and sees it as a potential additional commercial opportunity.
• Mosliciguat’s PH-ILD study showed a reported 56% placebo-adjusted reduction in pulmonary vascular resistance and a statistically significant 35-meter improvement in six-minute walk distance. Its Phase III study is enrolling, and Roivant is evaluating additional pulmonary hypertension and lung-disease indications.
• Roivant said its cutaneous lupus erythematosus program had not succeeded and that it is unlikely to advance IMVT-1402 in Sjögren’s syndrome, citing competitor results and other field updates. It plans to complete the ongoing Sjögren’s study and assess the remaining data.

Immunovant Trading Up 0.6%

IMVT opened at $35.37 on Tuesday. The firm’s 50-day moving average price is $32.98 and its 200 day moving average price is $32.15. Immunovant has a twelve month low of $21.86 and a twelve month high of $45.42. The firm has a market capitalization of $7.31 billion, a PE ratio of -12.49 and a beta of 0.95.

Immunovant News Summary

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: IMVT-1402 met the primary endpoint in a potentially registrational trial for difficult-to-treat rheumatoid arthritis: 92.5% of patients receiving the 600 mg dose achieved an ACR20 response at Week 28, versus 75.6% on placebo (p=0.0139). Exploratory ACR50 and ACR70 responses also reached 80.0% and 52.5%, respectively. Immunovant plans to discuss the next regulatory steps with the FDA later this year, making those discussions an important upcoming catalyst. Immunovant corporate updates and financial results
• Positive Sentiment: Immunovant reported a loss of $0.47 per share, narrower than analysts’ estimate of a $0.74 loss and the $0.73 loss a year earlier. The earnings beat may provide a modest positive alongside the clinical update. Second-quarter earnings results
• Negative Sentiment: The company said it is unlikely to advance IMVT-1402 in Sjögren’s disease beyond its ongoing, fully enrolled Phase 2 trial, citing the evolving landscape and recent data in the field. This narrows the drug’s potential development opportunities, though other clinical timelines remain on track. Immunovant corporate updates and financial results

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. JPMorgan Chase & Co. lifted their price objective on Immunovant from $47.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. UBS Group reaffirmed a “buy” rating on shares of Immunovant in a research report on Wednesday, September 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunovant in a research note on Friday, October 2nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunovant in a report on Tuesday, August 25th. Finally, Citigroup reaffirmed a “positive” rating on shares of Immunovant in a research note on Thursday, September 24th. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $44.00.

Insider Activity

In other news, CFO Tiago Girão sold 6,606 shares of the company’s stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $28.50, for a total transaction of $188,271.00. Following the sale, the chief financial officer owned 234,192 shares of the company’s stock, valued at approximately $6,674,472. This represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric Venker sold 3,506 shares of the business’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $34.11, for a total transaction of $119,589.66. Following the sale, the chief executive officer owned 257,075 shares of the company’s stock, valued at $8,768,828.25. This represents a 1.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 24,430 shares of company stock worth $787,852 over the last 90 days. Company insiders own 1.90% of the company’s stock.

About Immunovant

Immunovant, Inc is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies.

The company’s investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves’ disease and other autoimmune disorders.